Evidence map›Paper›PMID 42861287›Full record

ArticleFrontiers in toxicology2026

A pragmatic workflow for integrating large language models into toxicological risk assessment.

Arianna Bassan, Alexander Amberg, Maria Letizia Barreca, Paul M Bradley, Frank Bringezu, Joyce De Paula Souza, Corinne Guicheney, Elena Lo Piparo, Simona Kovarich, Andrey Massarsky and 13 more

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Arianna BassanInnovatune srl, Padova, Italy.
Alexander AmbergPreclinical Safety, Sanofi, Frankfurt, Germany.
Maria Letizia BarrecaIn Silico Drug Discovery Lab (I2D Lab), Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Paul M BradleyPaul Bradley Consulting, Royston, United Kingdom.
Frank BringezuMerck Healthcare KGaA, Darmstadt, Germany.
Joyce De Paula SouzaSwiss Centre for Applied Human Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Corinne GuicheneyGlobal Toxicology Services, KaLy-Cell, a Company of GBA Pharma, Plobsheim, France.
Elena Lo PiparoGlobal Regulatory Affairs, Sciences & Strategy, FMC, Geneva, Switzerland.
Simona KovarichGlobal Regulatory & Computational Toxicology Team, Hazard Communication and Chemicals Regulations, Merck Life Science S.r.l., Milan, Italy.
Andrey MassarskyStantec Consulting Services Inc., Irvine, CA, United States.
Georgia MaundrillMedicines Research Centre, GSK, Stevenage, United Kingdom.
Lance MolnarGlobal Pharmacology and Toxicology, Viatris, Morgantown, WV, United States.
Cristina ParentiEnvironment and Health Department, Istituto Superiore di Sanità, Rome, Italy.
Patricia ParrisPfizer Worldwide Research, Development and Medical, Sandwich, United Kingdom.
Manuela PavanInnovatune srl, Padova, Italy.
John F ReichardDepartment of Environmental and Public Health Sciences, University of Cincinnati, Cincinnati, OH, United States.
Ron SteigerwaltRon Steigerwalt Regulatory Tox Consulting, LLC, Palm Springs, CA, United States.
Olga TcheremenskaiaEnvironment and Health Department, Istituto Superiore di Sanità, Rome, Italy.
Kenneth UniceStrategic Health Sciences, TRC Companies, Pittsburgh, PA, United States.
Christopher J WaineBibra Toxicology Advice and Consulting, Wallington, Surrey, United Kingdom.
Geraldine WhelanMedicines Research Centre, GSK, Stevenage, United Kingdom.
Angela WhiteMedicines Research Centre, GSK, Stevenage, United Kingdom.
Glenn J MyattInformence Labs LLC, St. Petersburg, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI), particularly in the form of large language models (LLMs), offers promising support for toxicological risk assessment (TRA), which integrates multiple lines of evidence to support health-based conclusions, including those used in regulatory decision-making. Effective use of LLMs in TRA requires a clear understanding of their strengths and limitations, especially in the context of regulatory expectations for transparency, reproducibility, and accountability. This work explores the emerging role of LLMs in TRA through three integrated components: an overview of LLMs in the context of TRA, an exemplar case study examining LLM-assisted derivation (mainly using ChatGPT) of the Permitted Daily Exposure (PDE) for acetyl tributyl citrate under the draft ICH Q3E guideline, and a workflow hypothesis for the integration of LLMs into TRA. Observations from the case study suggest that LLMs may support pattern recognition, targeted information retrieval, and rapid summarization of large bodies of text, facilitating literature triage, extraction of study details, and evidence summaries. At the same time, the case study highlights important limitations for LLMs. Observed variability in LLM outputs reflects inherent model stochastic behavior, model limitations, and the intrinsic complexity of TRA, where different experts may reasonably reach distinct, yet scientifically defensible conclusions based on the available evidence. The observations from the case study, interpreted in the context of the available literature, are used to inform a hypothesis that LLMs may be most effectively integrated into TRA through structured, modular, human-supervised workflows. This hypothesis reflects the view that the suitability of LLM-assisted TRA depends not only on LLM capabilities, but also on how LLMs are integrated into the assessment process to address both LLM variability and the interpretive nature of TRA. The proposed pragmatic workflow separates data search, information extraction, and integrated summarization while maintaining human-in-the-loop control over interpretation, expert judgment, and final conclusions.

Indexed as

AIhuman-in-the-loopLLMPDEpragmatic workflowtoxicological risk assessment

Identifiers

PMID42861287
PMCPMC13654619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.